Shine Medical Technologies and Argonne National Laboratory have successfully demonstrated the production, separation, and purification of molybdenum-99 (Mo-99) from a liquid target provided by Shine.
The product purity of the resulting Mo-99 was equivalent to the Mo-99 currently being used in the supply chain. The demonstration uses the same process that will be used in the Shine manufacturing facility. It also validates the production chemistry from plant-relevant irradiation conditions through purification of Mo-99 to current industry standards. The work is supported by the U.S. Department of Energy's National Nuclear Security Administration Mo-99 program.
The Shine facility is expected to begin commercial production in 2018 and will be able to produce enough Mo-99 every year to supply two-thirds of the U.S. patient population, Argonne and Shine said.
